Clinical and histopathological features of immune-mediated necrotising and inflammatory myopathy in relation to treatment with immune checkpoint blockers (ICBs) in cancer patients


Immune checkpoint blockers (ICBs) of programmed death-1 receptor (PD1) are new efficient therapies for malignancies. Due to their mechanism of action, they can trigger various immune-related adverse events, among which myositis that we are going to describe in this retrospective case series of seven treated cancer patients. The following study entry criteria were used: (1) patients treated with ICBs for malignancy and addressed for muscle biopsy at Pitié-Salpêtrière Hospital or at Charité-University Hospital in Berlin from 2015 to 2017, (2) who exhibited objective muscle weakness supported by clinical examination and/or electromyography; (3) availability of cryopreserved skeletal muscle for extensive immunohistochemistry; (4) patients signed informed consent.


Leave A Reply